CP-690-550 Ointment For Chronic Plaque Psoriasis

Summary

The study is being conducted to see whether CP-690,550 ointment has potential as a safe and effective treatment for adult patients with mild to moderate chronic plaque psoriasis.

Timeline

Start

2011-02-16

Primary completion

2011-11-29

Completion

2011-11-29

Outcome

Mixed primary results

paper The primary endpoint of percentage change from baseline in the Target Plaque Severity Score at week 4 demonstrated statistically significant improvement for ointment 1 PMID 23387374 ↗

paper statistically significant improvement for ointment 1 [least squares mean (LSM) -54.4%] vs. vehicle 1 (LSM -41.5%), but not ointment 2 PMID 23387374 ↗

paper ointment 2 (LSM -24.2%) vs. vehicle 2 (LSM -17.2%). PMID 23387374 ↗

Publications

• Ports WC, Khan S, Lan S, Lamba M, Bolduc C, Bissonnette R, Papp K. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol. 2013 Jul;169(1):137-45. doi: 10.1111/bjd.12266.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tofacitinib	Small molecule	2 %	Topical

Indications